Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05239832
Recruitment Status : Active, not recruiting
First Posted : February 15, 2022
Last Update Posted : March 3, 2022
Sponsor:
Information provided by (Responsible Party):
Livzon Pharmaceutical Group Inc.

Brief Summary:
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines

Condition or disease Intervention/treatment Phase
COVID-19 Pandemic Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine Phase 2

Detailed Description:

This is a single arm, open-label clinical study. 34 participants aged 18 years and older who have completed the 2 doses of administration of inactive vaccines will be enrolled in this study to evaluate the safety and immunogenicity of V-01.

The participants will be collected blood before immunization, on day 7, day 14, day 28, day 90 and 6 month to evaluate humoral immunity.

All adverse events (AEs) within 30 minutes and 0-7 days after booster immunization, and unsolicited AEs from 8 to 28 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization will be collected from all participants.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Actual Study Start Date : August 5, 2021
Actual Primary Completion Date : September 29, 2021
Estimated Study Completion Date : August 5, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: V-01 COVID-19 Vaccine
10 μg(0.5ml)/vial, one dose administrated by intramuscular injection
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine
The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Other Name: V-01




Primary Outcome Measures :
  1. Incidence of adverse events (AEs) [ Time Frame: Within 12 months after booster immunization. ]
    The incidence of adverse events (AEs) occured within 30 minutes, 0-7 days, 0-30 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization.

  2. Geometric Mean Titer (GMT) [ Time Frame: 28 days after booster immunization ]
    GMT of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization

  3. Geometric Mean Increase (GMI) [ Time Frame: 28 days after booster immunization ]
    GMI of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization

  4. Seroconvension rate [ Time Frame: 28 days after booster immunization ]
    Seroconvension rate of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy participants aged 18 years and older who have completed the second dose of 2-dose regimen of SARS-CoV-2 vaccine (Vero cell) Inactivated in the past 3 months;
  2. Voluntarily participate in the study and sign the informed consent form, who can provide valid ID and follow the study protocol requirement;
  3. In the past 14 days, no history of high or medium risk of the epidemic, overseas travel history or residence history; no history of contact with confirmed, asymptomatic or suspected COVID-19 cases; no history of contact with the persons from high- and medium-risk epidemic areas or contact patients with fever or respiratory symptoms; and those who are not in isolation period.
  4. Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination.

Exclusion Criteria:

1. Confirmed COVID-19 cases, or positive for SARS-CoV-2 test by RT-PCR. 2. History of previous SARS infection. 3. Fever is suspected or diagnosed within 72 hours before enrollment, or the axillary body temperature ≥37.3℃ on the day of enrollment.

4. History of severe allergy to any vaccine or any ingredient of the vaccine including aluminum adjuvant, e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), dyspnea, angioedema, etc..

5. People who currently suffer from the following diseases:

  1. Symptoms related to acute respiratory infections (such as: sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.)
  2. Patients with thrombocytopenia, any coagulation dysfunction, or receive anticoagulant treatment, etc.
  3. Patients with congenital or acquired angioedema/neuroedema;
  4. A history of congenital or acquired immunodeficiency or autoimmune disease (except for mild psoriasis, controllable autoimmune thyroid disease, vitiligo, or stable celiac disease that does not require immunosuppressive or immunomodulatory therapy); no spleen , or history of spleen surgery, history of trauma, or treatment with immunomodulators within 6 months, such as: glucocorticoid with the dose causing immunosuppressive (dose reference: equivalent to prednisone 20mg/day, more than one week); or monoclonal antibody ; or thymosin; or interferon, etc.; but local medication (such as ointment, eye drops, inhalation or nasal spray) is allowed.
  5. Patients with active tuberculosis, viral hepatitis, human immunodeficiency virus or syphilis infection.
  6. Patients with acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases: history of chronic respiratory diseases (including moderate to severe asthma, COPD, pulmonary fibrosis), hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmHg) And/or diastolic blood pressure ≥100mmHg), history of severe cardiovascular disease (including heart failure, coronary artery disease, cardiomyopathy), history of chronic kidney disease, history of cancer (except for basal cell carcinoma), diabetes (unsatisfied blood sugar control or diabetes related serious complications).

6. Received attenuated live vaccine within 28 days before the vaccination or any subunit vaccines and inactivated vaccines within 14 days before the vaccination.

7. Injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; or with the plan to use such product within 6 month after immunization.

8. Pregnant (including positive urine pregnancy test for women of childbearing age) or breastfeeding women. Or women or their partners who have a pregnancy plan within 3 months after the trial vaccination.

9. Have participated in or are participating in other COVID-19 related clinical trials, or are participating in other drug clinical trials; 10. Those considered by the investigator as inappropriate to participate in the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05239832


Locations
Layout table for location information
China, Guangdong
The Fifth Peoples' Hospital of Zhuhai
Zhuhai, Guangdong, China, 519000
Sponsors and Collaborators
Livzon Pharmaceutical Group Inc.
Layout table for additonal information
Responsible Party: Livzon Pharmaceutical Group Inc.
ClinicalTrials.gov Identifier: NCT05239832    
Other Study ID Numbers: V-01-Booster-01
First Posted: February 15, 2022    Key Record Dates
Last Update Posted: March 3, 2022
Last Verified: February 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases